Parabilis Medicines (PBLS) Competitors

Parabilis Medicines logo
$28.45 +0.02 (+0.07%)
As of 04:00 PM Eastern

PBLS vs. SMMT, HALO, KYMR, BMRN, and PCVX

Should you buy Parabilis Medicines stock or one of its competitors? Parabilis Medicines's main competitors and comparable companies include Summit Therapeutics (SMMT), Halozyme Therapeutics (HALO), Kymera Therapeutics (KYMR), BioMarin Pharmaceutical (BMRN), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Parabilis Medicines compare to Summit Therapeutics?

Parabilis Medicines (NASDAQ:PBLS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Parabilis Medicines' return on equity of -73.69% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A -73.69% -25.40%
Summit Therapeutics N/A -138.82%-117.11%

4.6% of Summit Therapeutics shares are held by institutional investors. 81.8% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Parabilis Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/A-$145.89M-$2.13N/A
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A

Parabilis Medicines presently has a consensus price target of $40.80, indicating a potential upside of 43.51%. Summit Therapeutics has a consensus price target of $28.61, indicating a potential upside of 102.17%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Parabilis Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58

In the previous week, Parabilis Medicines had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Parabilis Medicines and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Parabilis Medicines' score of 0.58 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Parabilis Medicines
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Summit Therapeutics beats Parabilis Medicines on 7 of the 12 factors compared between the two stocks.

How does Parabilis Medicines compare to Halozyme Therapeutics?

Parabilis Medicines (NASDAQ:PBLS) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Parabilis Medicines presently has a consensus target price of $40.80, suggesting a potential upside of 43.51%. Halozyme Therapeutics has a consensus target price of $108.18, suggesting a potential upside of 7.89%. Given Parabilis Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe Parabilis Medicines is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

Halozyme Therapeutics has higher revenue and earnings than Parabilis Medicines. Parabilis Medicines is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/A-$145.89M-$2.13N/A
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51

Halozyme Therapeutics has a net margin of 26.93% compared to Parabilis Medicines' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Parabilis Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A -73.69% -25.40%
Halozyme Therapeutics 26.93%751.81%23.84%

In the previous week, Parabilis Medicines and Parabilis Medicines both had 12 articles in the media. Parabilis Medicines' average media sentiment score of 0.58 beat Halozyme Therapeutics' score of 0.13 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Parabilis Medicines
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics beats Parabilis Medicines on 10 of the 14 factors compared between the two stocks.

How does Parabilis Medicines compare to Kymera Therapeutics?

Parabilis Medicines (NASDAQ:PBLS) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Parabilis Medicines had 8 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Parabilis Medicines and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Parabilis Medicines' score of 0.58 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Parabilis Medicines
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Parabilis Medicines has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Parabilis Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/A-$145.89M-$2.13N/A
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A

Parabilis Medicines presently has a consensus price target of $40.80, suggesting a potential upside of 43.51%. Kymera Therapeutics has a consensus price target of $139.16, suggesting a potential upside of 9.09%. Given Parabilis Medicines' higher probable upside, research analysts plainly believe Parabilis Medicines is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

Parabilis Medicines has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -22.39% beat Parabilis Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A -73.69% -25.40%
Kymera Therapeutics -285.33%-22.39%-20.48%

Summary

Parabilis Medicines and Kymera Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Parabilis Medicines compare to BioMarin Pharmaceutical?

Parabilis Medicines (NASDAQ:PBLS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

In the previous week, Parabilis Medicines had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 12 mentions for Parabilis Medicines and 9 mentions for BioMarin Pharmaceutical. Parabilis Medicines' average media sentiment score of 0.58 beat BioMarin Pharmaceutical's score of 0.35 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Parabilis Medicines
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BioMarin Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Parabilis Medicines presently has a consensus price target of $40.80, indicating a potential upside of 43.51%. BioMarin Pharmaceutical has a consensus price target of $87.22, indicating a potential upside of 52.40%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Parabilis Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Parabilis Medicines has a net margin of 0.00% compared to BioMarin Pharmaceutical's net margin of -0.52%. BioMarin Pharmaceutical's return on equity of 5.58% beat Parabilis Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A -73.69% -25.40%
BioMarin Pharmaceutical -0.52%5.58%3.51%

BioMarin Pharmaceutical has higher revenue and earnings than Parabilis Medicines. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Parabilis Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/A-$145.89M-$2.13N/A
BioMarin Pharmaceutical$3.22B3.44$348.90M-$0.10N/A

Summary

BioMarin Pharmaceutical beats Parabilis Medicines on 11 of the 15 factors compared between the two stocks.

How does Parabilis Medicines compare to Vaxcyte?

Parabilis Medicines (NASDAQ:PBLS) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Parabilis Medicines is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/A-$145.89M-$2.13N/A
VaxcyteN/AN/A-$766.63M-$8.06N/A

Parabilis Medicines currently has a consensus target price of $40.80, indicating a potential upside of 43.51%. Vaxcyte has a consensus target price of $110.50, indicating a potential upside of 74.37%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Parabilis Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Vaxcyte's return on equity of -42.04% beat Parabilis Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A -73.69% -25.40%
Vaxcyte N/A -42.04%-36.82%

In the previous week, Parabilis Medicines and Parabilis Medicines both had 12 articles in the media. Vaxcyte's average media sentiment score of 0.88 beat Parabilis Medicines' score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Parabilis Medicines
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Vaxcyte beats Parabilis Medicines on 7 of the 12 factors compared between the two stocks.

Get Parabilis Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBLS vs. The Competition

MetricParabilis MedicinesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.42B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.39
Price / SalesN/A16.028.595.74
Price / CashN/A26.3721.9322.50
Price / BookN/A4.074.403.70
Net Income-$145.89M-$22.86M$3.52B$392.17M
7 Day Performance-6.32%-7.26%-5.34%-4.53%
1 Month Performance25.05%-4.96%-3.61%-5.86%
1 Year PerformanceN/A-2.87%0.01%-7.78%

Parabilis Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBLS
Parabilis Medicines
2.817 of 5 stars
$28.45
+0.1%
$40.80
+43.4%
N/A$3.42BN/AN/A145
SMMT
Summit Therapeutics
2.6441 of 5 stars
$15.07
-9.4%
$28.61
+89.8%
-21.5%$13.31BN/AN/A265
HALO
Halozyme Therapeutics
4.26 of 5 stars
$100.67
-1.0%
$108.18
+7.5%
+43.2%$11.59B$1.80B25.62423
KYMR
Kymera Therapeutics
2.0649 of 5 stars
$127.17
-5.7%
$139.16
+9.4%
+96.4%$11.51B$39.21MN/A285
BMRN
BioMarin Pharmaceutical
4.4302 of 5 stars
$56.70
-2.8%
$87.91
+55.0%
+4.6%$11.30B$3.22B32.773,221

Related Companies and Tools


This page (NASDAQ:PBLS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners